Category:
Prophylactic Biological Products
CAS NO:
119413-54-6
Standard:
ChP,IP,
Compared with camptothecin, Topotecan hydrochloride has lower toxicity and higher anti-tumor activity. It was approved for market in 1996 and is clinically used for the treatment of advanced colon cancer, rectal cancer, ovarian cancer and small cell lung cancer
Topotecan hydrochloride is a semi-synthetic topoisomerase I inhibitor derived from camptothecin. It is produced via chemical synthesis and purification. Molecular formula: C23H28ClN2O6; CAS No.: 121702-45-6.
Strictly store below -20°C to maintain stability. Handling requires PPE due to cytotoxicity. Contraindicated in severe neutropenia or pregnancy. Adhere to GMP guidelines for pharmaceutical production.